2:53 PM
 | 
Jan 08, 2018
 |  BC Extra  |  Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) gained €9.60 (45%) to €30.80 in Brussels and $12.71 (49%) to $38.62 in New York on Monday after making public news that its board rejected two unsolicited acquisition proposals from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Ablynx said in a statement the latest proposal "fundamentally undervalues" the company.

On Dec. 22, Novo proposed to acquire Ablynx for...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >